Clinical Trials Browser

Hodgkin Disease × Brentuximab Vedotin × Clear all

NCT05922904 2026-04-15

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Phase 2 Active not recruiting

Hodgkin Disease

NCT03907488 2026-04-13

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3 Active not recruiting

994 enrolled 11 charts 2 FDA

Hodgkin Disease

NCT05481437 2026-04-13

A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

Hodgkin Disease

NCT04685616 2026-03-30

RADAR

Phase 3 Recruiting

Hodgkin Disease

NCT01712490 2026-02-27

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Phase 3 Completed

1,334 enrolled 23 charts

Hodgkin Disease, Lymphoma

NCT03755804 2026-02-23

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Phase 2 Active not recruiting

Hodgkin Disease, Neoplasms

NCT06831370 2026-02-23

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Phase 4 Recruiting

Hodgkin Disease, Lymphoma

NCT02684292 2026-02-18

MK-3475-204

Phase 3 Completed

304 enrolled 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT05180097 2026-02-02

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT01920932 2025-12-03

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Phase 2 Active not recruiting

77 enrolled 20 charts

Hodgkin Disease, Neoplasms

NCT02227199 2025-11-18

BV-ICE

Phase 1/2 Completed

45 enrolled 14 charts

Hodgkin Disease

NCT02979522 2025-11-10

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Phase 1/2 Active not recruiting

59 enrolled 63 charts

Hodgkin Disease

NCT07002216 2025-11-03

BrECADD

Phase 2 Recruiting

Hodgkin Disease

NCT01508312 2025-10-21

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

66 enrolled 14 charts

Hodgkin Disease

NCT03646123 2025-08-28

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Phase 2 Terminated

255 enrolled 29 charts

Hodgkin Disease

NCT01868451 2025-07-09

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Phase NA Active not recruiting

Hodgkin Disease

NCT01703949 2025-06-11

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Phase 2 Active not recruiting

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT03057795 2025-05-07

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Phase 2 Active not recruiting

62 enrolled 8 charts

Hodgkin Disease

NCT06377566 2025-04-20

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT02744612 2025-03-26

Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

39 enrolled 9 charts

Hodgkin Disease

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2/3 Recruiting

Hodgkin Disease, Recurrence

NCT02927769 2025-02-10

CheckMate 744

Phase 2 Completed

72 enrolled 24 charts

Hodgkin Disease

NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Phase 4 Not yet recruiting

Hodgkin Disease, Recurrence

NCT03712202 2024-11-06

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Phase 2 Active not recruiting

Hodgkin Disease

NCT02191930 2024-08-23

BVB

Phase 2 Completed

Hodgkin Disease

NCT01716806 2024-06-11

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Phase 2 Completed

131 enrolled 28 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Peripheral

NCT01492088 2024-05-30

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Phase 1/2 Completed

36 enrolled 26 charts

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT04378647 2024-02-26

BRESELIBET

Phase 2 Recruiting

Hodgkin Disease

NCT03013933 2024-02-22

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Completed

Hodgkin Disease

NCT06201507 2024-01-12

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Phase 2 Unknown

Hodgkin Disease

NCT03138499 2024-01-10

CheckMate 812

Phase 3 Terminated

23 enrolled 14 charts

Hodgkin Disease

NCT02398240 2023-10-26

Brentuximab for Newly Diagnosed Hodgkin Disease

Phase 2 Completed

Hodgkin Disease

NCT03947255 2023-10-13

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Phase 2 Terminated

12 enrolled 17 charts

Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT02572167 2022-11-08

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

93 enrolled 13 charts

Hodgkin Disease

NCT02098512 2022-10-27

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Phase 1/2 Unknown

Hodgkin Disease

NCT02292979 2022-08-19

BREACH

Phase 2 Completed

Hodgkin Disease

NCT03302728 2022-05-19

EpiBrentlen

Phase 1 Completed

DermatologicLymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02429375 2022-05-12

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

7 enrolled 10 charts

Hodgkin Disease, Recurrence

NCT01578967 2021-12-07

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Phase NA Completed

41 enrolled 14 charts

Hodgkin Disease

NCT02686346 2021-12-07

BV-ICE

Phase 1/2 Completed

Hodgkin Disease, Recurrence

NCT01780662 2021-10-28

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

46 enrolled 18 charts

Hodgkin Disease

NCT01805037 2021-09-01

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Phase 1/2 Terminated

20 enrolled 17 charts

DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Epstein-Barr Virus Infections, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT02298283 2021-07-26

BRAPP2

Phase 2 Completed

Hodgkin Disease

NCT01100502 2021-05-14

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Phase 3 Completed

329 enrolled 15 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Phase 4 Completed

60 enrolled 21 charts

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02939014 2021-02-24

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Phase 2 Completed

39 enrolled 26 charts

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

NCT02227433 2020-12-22

FIL_BVHD01

Phase 2 Completed

Hodgkin Disease

NCT01196208 2020-09-21

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

No longer available

DermatologicLymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT02505269 2020-08-24

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Phase 2 Completed

34 enrolled 7 charts

Hodgkin Disease

NCT03474133 2020-07-21

BASALT

Phase 2 Unknown

Hodgkin Disease, Recurrence